Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

65,437 trials

Phase 2 N=1,808 Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

Acute Non-cardioembolic Ischemic Stroke
Primary: Efficacy-Number of Participants With Composite of Symptomatic Ischemic Stroke or Covert Brain Infarcts Detected by Magnetic Resonance Imaging (MRI) — 24; 25; 17; 23…
Bayer Results Apr 2023 20.4% serious AE View details

Phase 2 N=15 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

B-Cell Chronic Lymphocytic Leukemia · B-Lymphocytic Leukemia, Chronic · Chronic Lymphocytic Leukemia
Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…
National Heart, Lung, and Blood Institute (NHLBI) Results Apr 2023 73.3% serious AE View details

Phase 1 N=29 Trial to Evaluate CIS43LS in Healthy Adults

Malaria
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of CIS43LS Product Administration — 4; 1; 5; 3 Participants
National Institute of Allergy and Infectious… Results Apr 2023 1.5% serious AE View details

N/A N=25 Minocycline in the Treatment of Angelman Syndrome

Angelman Syndrome
Primary: Bayley Scales of Infant and Toddler Development, 2nd Edition (BSID-II) Score at Baseline, 8 Weeks After Treatment, and at 16 Week Follow-up — 26.4; 31.7; 30.7; 18.9…
University of South Florida Results Apr 2023 12.0% serious AE View details